Skip to main content
Fig. 8 | BMC Cancer

Fig. 8

From: Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

Fig. 8

Evaluation of cross-resistance to common nucleoside analogues. Assessment of Z138-CytNS and Z138-CytR cell proliferation after treatment of cells for 48 h with different concentrations of four different nucleoside analogues, including cytarabine, gemcitabine, cladribine and fludarabine. The data are normalized to the 0-h time-point, and visualized as relative to the DMSO vehicle control. Each data point represents mean of three independent experiments

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us